S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

$10.94
-0.12 (-1.08%)
(As of 03/27/2024 ET)
Today's Range
$10.86
$11.27
50-Day Range
$10.62
$11.73
52-Week Range
$10.29
$16.91
Volume
224,870 shs
Average Volume
250,536 shs
Market Capitalization
$19.80 billion
P/E Ratio
27.95
Dividend Yield
3.11%
Price Target
N/A
ALPMY stock logo

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

ALPMY Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Q4 2023 Taysha Gene Therapies Inc Earnings Call
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Astellas Makes Announcement about Management Structure
Astellas Pharma Announces Collaboration With Mass General Brigham
Astellas Pharma Inc. ADR
See More Headlines
Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
3/27/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,484
Year Founded
1923

Profitability

Net Income
$742 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.24 billion
Cash Flow
$1.36 per share
Book Value
$6.27 per share

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$19.80 billion
Optionable
Not Optionable
Beta
0.32

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Naoki Okamura BSc (Age 62)
    President, CEO & Director
    Comp: $984.33k
  • Mr. Atsushi Kitamura
    Chief Financial Officer
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 57)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Collette Taylor (Age 61)
    Senior Vice President of Human Resources
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive

Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Astellas Pharma was last updated on Tuesday, March 26, 2024 at 12:06 AM.

Pros

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • Astellas Pharma Inc. has a diverse portfolio of pharmaceutical products, including XTANDI, XOSPATA, PADCEV, and Evrenzo, catering to various medical needs and potentially ensuring stable revenue streams.
  • The company has shown resilience in the market with a 52-week low of $10.29 and a 52-week high of $16.91, indicating potential for growth and recovery.
  • Astellas Pharma Inc. reported a positive quarterly earnings result with $0.12 earnings per share, demonstrating financial stability and growth potential.
  • The company has a market capitalization of $19.59 billion, reflecting its significant presence and stability in the pharmaceutical industry.
  • Equities analysts expect Astellas Pharma to post 0.28 EPS for the current fiscal year, suggesting potential for positive returns for investors.

Cons

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • Short interest in Astellas Pharma Inc. increased by 9.1% in February, indicating potential market skepticism or uncertainty surrounding the company's performance.
  • The company's stock price has experienced fluctuations, with a current trading volume below the average volume, suggesting possible volatility in the market.
  • Astellas Pharma Inc. has a P/E ratio of 27.59 and a P/E/G ratio of 2.60, which may indicate that the stock is relatively overvalued compared to its growth prospects.
  • The company's net margin of 0.08% and return on equity of 6.39% may raise concerns about profitability and efficiency in utilizing shareholder equity.
  • Astellas Pharma Inc. has a debt-to-equity ratio of 0.31, a current ratio of 0.91, and a quick ratio of 0.71, which could signal potential financial risks or liquidity challenges.

ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALPMY shares.
View ALPMY analyst ratings
or view top-rated stocks.

How have ALPMY shares performed in 2024?

Astellas Pharma's stock was trading at $11.90 on January 1st, 2024. Since then, ALPMY shares have decreased by 8.1% and is now trading at $10.94.
View the best growth stocks for 2024 here
.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 112,200 shares, an increase of 51.6% from the February 29th total of 74,000 shares. Based on an average trading volume of 555,200 shares, the short-interest ratio is currently 0.2 days.
View Astellas Pharma's Short Interest
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its quarterly earnings data on Monday, February, 5th. The company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $2.86 billion for the quarter. Astellas Pharma had a trailing twelve-month return on equity of 6.39% and a net margin of 0.08%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.34 per share and currently has a dividend yield of 3.08%.

When did Astellas Pharma's stock split?

Shares of Astellas Pharma split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
This page (OTCMKTS:ALPMY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners